Sunday, 22 Mar 2026
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • 🔥
  • Trump
  • House
  • ScienceAlert
  • VIDEO
  • White
  • man
  • Trumps
  • Season
  • star
  • Watch
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Economy > Here’s What to Expect From Johnson & Johnson’s Next Earnings Report
Economy

Here’s What to Expect From Johnson & Johnson’s Next Earnings Report

Last updated: June 28, 2025 4:00 am
Share
Here’s What to Expect From Johnson & Johnson’s Next Earnings Report
SHARE

Johnson & Johnson (JNJ) is a leading healthcare company headquartered in New Brunswick, New Jersey. The company is known for its research and development, manufacturing, and sale of various healthcare products worldwide. With a market capitalization of $366.4 billion, Johnson & Johnson operates through its Innovative Medicine and MedTech segments.

The company is gearing up to announce its second-quarter results on Wednesday, July 16. Analysts are projecting a non-GAAP earnings of $2.65 per share, a 6% decrease from the previous year. Despite the anticipated decline, Johnson & Johnson has consistently exceeded analysts’ expectations in recent quarters. For the full fiscal year 2025, earnings are expected to reach $10.60 per share, representing a 6.2% increase from the previous year. In fiscal 2026, earnings are projected to rise by 3.6% year-over-year to $10.98 per share.

Over the past 52 weeks, JNJ stock has shown a 3.5% growth, outperforming the Health Care Select Sector SPDR Fund’s 8.1% decline but falling short of the S&P 500 Index’s 12.1% increase during the same period. Despite delivering better-than-expected financial results in the first quarter, Johnson & Johnson’s stock experienced a slight dip initially. However, the company’s solid growth in US sales led to a 2.4% year-over-year increase in overall revenue to $21.9 billion. Additionally, adjusted earnings per share rose by 2.2% to $2.77, exceeding consensus estimates.

Analysts have a cautiously optimistic outlook on JNJ, with a “Moderate Buy” rating overall. Of the 23 analysts covering the stock, nine rate it as a “Strong Buy,” two as a “Moderate Buy,” and 12 as a “Hold.” The mean price target of $169.14 suggests an 11.3% upside potential from the current price levels.

See also  Manchester United working to land Sporting Lisbon's Ruben Amorim as Erik ten Hag's successor, per report

In conclusion, Johnson & Johnson continues to demonstrate resilience and growth in the healthcare industry. Investors are eagerly awaiting the company’s upcoming earnings report to gain further insights into its financial performance and future outlook. This article was originally published on Barchart.com and is intended for informational purposes only.

TAGGED:EarningsExpectHeresJohnsonJohnsonsreport
Share This Article
Twitter Email Copy Link Print
Previous Article Creating Bird Flu Vaccines for Humans at a Biosecure Laboratory Creating Bird Flu Vaccines for Humans at a Biosecure Laboratory
Next Article Summer 2025 Hot Shots … June Gloom?! More Like June Bloom! Summer 2025 Hot Shots … June Gloom?! More Like June Bloom!
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

See 13 Captivating Images From the Wildlife Photographer of the Year Contest

South African photographer William Fortescue captured this dramatic scene of two lions mating during a…

September 6, 2024

The 14th Taipei Biennial Explores Collective Yearning and Shared Futures

The Taipei Biennial is back with its 14th edition, titled "Whispers on the Horizon," curated…

September 20, 2025

Goolsbee vs. Summers – Econlib

In a recent article on Bloomberg, two prominent economists shared their perspectives on the strong…

October 4, 2024

Rag & Bone Pre-Fall 2026 Collection

Rag & Bone: Creating Clothing with Hanger AppealAt Rag & Bone, Jennie McCormick and her…

November 13, 2025

Tesla Seeing Strong Demand For Cheaper Cybertruck, But Musk’s 10-Day Deadline Remains In Place

After struggling to sell Cybertrucks, Tesla Inc (NASDAQ: TSLA) is now experiencing a surge in…

March 1, 2026

You Might Also Like

JPMorgan CEO Jamie Dimon said this asset could soar to ‘,000,’ despite dismissing it before. How 2026 is shaping up
Economy

JPMorgan CEO Jamie Dimon said this asset could soar to ‘$10,000,’ despite dismissing it before. How 2026 is shaping up

March 22, 2026
Best high-yield savings interest rates today, March 21, 2026 (Earn up to 4% APY)
Economy

Best high-yield savings interest rates today, March 21, 2026 (Earn up to 4% APY)

March 22, 2026
Is Salesforce a good long-term investment? Its buy-and-hold prospects explained
Economy

Is Salesforce a good long-term investment? Its buy-and-hold prospects explained

March 21, 2026
Evercore and Goldman Sachs Stay Bullish on Arista Networks (ANET)
Economy

Evercore and Goldman Sachs Stay Bullish on Arista Networks (ANET)

March 21, 2026
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?